LivaNova PLC (LIVN) stock plummeted 5.27% in Tuesday's pre-market trading session, underperforming the broader market. The medical technology company reported mixed fourth-quarter results, with earnings beating estimates but revenue missing expectations.
For Q4, LivaNova reported adjusted earnings per share of $0.81, slightly above the consensus estimate of $0.80. However, revenue came in at $321.8 million, missing analysts' expectations of $324.1 million. The company's full-year revenue grew by 3.77% compared to the previous year.
Furthermore, LivaNova's 2025 guidance disappointed investors. The company expects adjusted EPS in the range of $3.65 to $3.75, slightly below the FactSet consensus estimate of $3.66. Revenue growth is projected to be between 5% and 6% on a constant-currency basis and 6% to 7% on an organic basis.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。